Pinetree out-licenses option for pan-EGFR degrader
July 24, 2024
Pinetree Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc for a preclinical epidermal growth factor receptor (EGFR) degrader candidate.